Cambrex's Innovative Liquid-Phase Peptide Synthesis Technology
Cambrex, a well-known name in the global contract development and manufacturing organization sector, recently made waves by announcing its cutting-edge liquid-phase peptide synthesis (LPPS) technology. Pioneered by Snapdragon Chemistry, a subsidiary of Cambrex, this groundbreaking approach combines traditional batch reactors used for active pharmaceutical ingredients with continuous flow techniques. This advancement not only streamlines peptide synthesis but also addresses the limitations of solid-phase reactors, greatly enhancing pharmaceutical manufacturing capabilities.
Major Benefits of Liquid-Phase Peptide Synthesis
The LPPS technology represents a significant evolution in peptide manufacturing, offering numerous advantages over conventional solid-state peptide synthesis. A key benefit is the considerable reduction in solvent use, which makes production methods more environmentally friendly. Additionally, this new approach requires fewer excess reagents, leading to improved efficiency throughout the entire synthesis process. As the demand for peptides and oligonucleotides keeps growing, innovations like this are vital for catering to market needs while promoting sustainable practices.
Enhanced Scalability and Flexibility
This state-of-the-art technology can efficiently support the synthesis of peptides up to 12 residues long. For larger peptides, the liquid-phase assembly method integrates convergent fragment coupling for optimal results. This flexibility means that processes using Cambrex's LPPS technology can be scaled similarly to conventional small molecule methods, making it easier to produce complex peptide structures.
Advancements in Peptide and Protein Technologies
In addition to enhancing LPPS technology, Cambrex is also working to improve its processes for peptide and protein crystallization. These advancements include a specialized crystallization screening platform designed to identify crystalline forms of peptides and proteins. Crystallization is crucial for boosting product quality and stability while reducing the need for labor-intensive preparative chromatography and lyophilization. Such improvements reflect Cambrex's dedication to ongoing innovation and enhancement of manufacturing processes.
Industry Growth and Continued Investments
With the rising success of peptide-based therapies in both clinical and commercial arenas, Cambrex is poised to meet the increasing demand for these treatments. Dr. Matt Bio, the Chief Scientific Officer at Cambrex, emphasized the importance of delivering cutting-edge solutions for developing and scaling peptide candidates. The company remains committed to investing in research and development, particularly focusing on complex synthetic methods and exploring how artificial intelligence can further improve oligonucleotide processes.
About Snapdragon Chemistry
Snapdragon Chemistry, an integral part of Cambrex, excels in both API batch and continuous flow process development. Utilizing advanced automation technology and proprietary equipment, the company tackles a range of complex process and analytical development challenges. Headquartered in Massachusetts, Snapdragon employs over 70 professionals, including 31 PhD scientists, which helps foster strong ties with the local scientific community.
About Cambrex
Cambrex brings over 40 years of experience in the pharmaceutical industry as a leading CDMO. The organization offers services that span the entire drug lifecycle, including drug substance development, comprehensive analytical services, and IND enabling solutions. With a diverse workforce of 2,000 skilled professionals, Cambrex serves clients globally from regions such as North America and Europe. Their array of specialized drug substance technologies encompasses continuous flow, controlled substances, solid-state science, material characterization, and potent APIs.
Frequently Asked Questions
What is the new LPPS technology introduced by Cambrex?
The LPPS technology is an innovative approach to peptide synthesis developed by Cambrex, utilizing traditional batch reactors and continuous flow methods to reduce solvent usage and increase efficiency.
How does the LPPS technology impact sustainability?
By significantly reducing solvent demand and the need for excess reagents, the LPPS technology promotes environmentally friendly practices in peptide manufacturing.
In what ways can the LPPS technology be scaled?
The processes developed with Cambrex's LPPS technology can be scaled similarly to traditional small molecules, making production of complex peptides more feasible.
What additional capabilities has Cambrex developed alongside LPPS?
Cambrex has also improved its capabilities in peptide and protein crystallization, supporting better product quality and stability through advanced screening platforms.
What is Cambrex’s commitment to research and development?
Cambrex is dedicated to ongoing investment in R&D, focusing on complex synthetic modalities and the application of AI to optimize oligonucleotide processes.